Risk factors and clinical characteristics of patients with nosocomial influenza A infection

J Med Virol. 2020 Aug;92(8):1047-1052. doi: 10.1002/jmv.25652. Epub 2019 Dec 19.

Abstract

Influenza is a public health burden, responsible for more than half a million deaths worldwide each year and explosive outbreaks in-hospital care units. At present, little is known about clinical characteristics and outcomes with nosocomial influenza infection. To assess clinical characteristics and outcome between nosocomial and community-acquired (CA) influenza in a tertiary care hospital. A retrospective study of hospitalized patients in a French tertiary care hospital from 1st December 2016 to 28th February 2017 for flu-illness confirmed by reverse transcription PCR. Overall, 208 patients with laboratory-confirmed influenza were included; whose 49 nosocomial cases (23.6%). Patients with nosocomial influenza were significantly older (79.1 ± 15.5 vs 64.8 ± 31.1 years old; P = .003), with the more rapidly fatal disease (10.2% vs 1.3%; P = .0032). They had a less respiratory failure (8.2% vs 21.4%; P = .036) but had a longer length of hospitalization (47.3 vs 12.9 days; P < .001) than patients with CA influenza. During this influenza outbreak, 19 patients died (9.1%), none of them were vaccinated. Effective control of outbreaks in hospital facilities is challenging. Hospitalized patients are vulnerable to nosocomial Influenza infections that can increase the length of stay and be responsible for the death. Surveillance and early warning systems should be encouraged. Vaccination policies in conjunction with isolation measures and better hand hygiene could reduce virus spreading in hospitals.

Keywords: healthcare-associated infection; hospitalized adults; influenza; nosocomial; outbreak.

MeSH terms

  • Age Factors
  • Aged
  • Community-Acquired Infections / epidemiology
  • Community-Acquired Infections / mortality
  • Community-Acquired Infections / physiopathology
  • Cross Infection / epidemiology*
  • Cross Infection / mortality
  • Cross Infection / physiopathology
  • Female
  • Humans
  • Immune Tolerance
  • Influenza A virus*
  • Influenza Vaccines
  • Influenza, Human / epidemiology*
  • Influenza, Human / mortality
  • Influenza, Human / physiopathology
  • Length of Stay
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Tertiary Care Centers
  • Vaccination

Substances

  • Influenza Vaccines